Amifampridine (3,4-diaminopyridine) is a potassium-channel blocker used to improve neuromuscular transmission. Its primary clinical uses are in the treatment of Lambert–Eaton myasthenic syndrome (LEMS) and symptomatic management of certain congenital and acquired neuromuscular transmission disorders. The market includes originator/patented presentations, authorized generics, plain gen... https://www.researchnester.com/reports/amifampridine-market/7694